Standout Papers

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-con... 2008 2026 2014 2020 2.3k
  1. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial (2008)
    Robert J. Motzer, Bernard Escudier et al. The Lancet
  2. Everolimus for Advanced Pancreatic Neuroendocrine Tumors (2011)
    James C. Yao, Manisha H. Shah et al. New England Journal of Medicine
  3. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study (2011)
    Marianne Pavel, John D. Hainsworth et al. The Lancet
  4. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial (2013)
    John J. Bissler, J.C. Kingswood et al. The Lancet
  5. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial (2012)
    David Neal Franz, Е. Д. Белоусова et al. The Lancet
  6. Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis (2013)
    Denise A. Yardley, Shinzaburo Noguchi et al. Advances in Therapy
  7. Everolimus for Previously Treated Advanced Gastric Cancer: Results of the Randomized, Double-Blind, Phase III GRANITE-1 Study (2013)
    Atsushi Ohtsu, Jaffer A. Ajani et al. Journal of Clinical Oncology

Immediate Impact

3 by Nobel laureates 12 from Science/Nature 68 standout
Sub-graph 1 of 19

Citing Papers

Glioblastoma and Other Primary Brain Malignancies in Adults
2023 Standout
Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211)
2022 Standout
12 intermediate papers

Works of David Lebwohl being referenced

Everolimus for Advanced Pancreatic Neuroendocrine Tumors
2011 Standout
Daily Oral Everolimus Activity in Patients With Metastatic Pancreatic Neuroendocrine Tumors After Failure of Cytotoxic Chemotherapy: A Phase II Trial
2009
and 2 more

Author Peers

Author Last Decade Papers Cites
David Lebwohl 5202 3284 1668 3408 43 9.4k
Tarek Sahmoud 5060 4830 1789 2034 129 11.1k
Helen X. Chen 4050 2512 1937 3819 83 8.7k
Charles M. Baum 4641 8095 3322 5831 70 12.6k
Emily K. Bergsland 6965 1729 1545 3096 198 10.7k
Dara L. Aisner 3641 4641 1790 3360 127 7.8k
Xin Huang 5275 6909 2738 2751 96 10.0k
Rosine Guimbaud 7517 2452 2328 1503 177 9.3k
Young Lim Choi 5618 6699 2858 4886 62 10.4k
Ronit Simantov 3293 4224 2630 5436 87 11.0k
Manabu Soda 5897 7211 2830 4623 46 10.3k

All Works

Loading papers...

Rankless by CCL
2026